An open-label positron emission tomography (PET) study to investigate and quantify brain and tumor penetration of carbon-11 labeled lapatinib in patients with HER2-overexpressing (HER2+) advanced or metastatic breast cancer (MBC).
R. C. Coombes
No relevant relationships to disclose
J. A. Reise
No relevant relationships to disclose
M. Lau
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
S. C. Carme
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
G. E. Searle
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
M. Huiban
Employment or Leadership Position - GlaxoSmithKline
P. Burgess
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
K. Koch
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
A. Das-Gupta
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
A. Saleem
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline